Persistent formation of eIF4F complex has been suggested to be a nexus of resistance to anti-BRAF and anti-MEK cancer therapies regardless of whether the resistance mechanisms rely on reactivation of the Raf/MEK/ERK pathway, activation of the PI3K/AKT/mTOR pathway, or modulation of the caspase-dependent apoptotic cascade [58]. Here, BRAF is linked to cancer.